Depatuxizumab mafodotin (ABT-414) is monoclonal antibody-drug conjugate that binds to EGFR amplified on GBM and works against tumor through EGFR blockage and tubulin polymerization by conjugated tubulin inhibitor monomethyl auristatin F. Recently, ABT-414 demonstrated a median OS of 10.7 months in recurrent GBM patients 76. Here, EGFR is linked to glioblastoma.